Key facts
- This page summarizes Gina Chapman's Form 4 filing for CARGO Therapeutics, Inc. (CRGX).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Sep 2024, 17:24.
Gina Chapman - 18 Sep 2024 Form 4 Insider Report for CARGO Therapeutics, Inc. (CRGX)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- CRGX
- Reported as of
- 18 Sep 2024
- Net transaction value
- -$203,222
- SEC form
- 4
- Accepted by SEC
- 20 Sep 2024, 17:24:58 UTC
- Prior SEC filing
- 14 Jun 2024
- Next SEC filing
- 18 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Halley Gilbert, as attorney-in-fact for Gina Chapman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gina Chapman filed Form 4 for CARGO Therapeutics, Inc. (CRGX) on 20 Sep 2024.
Change
- Previous filing in this sequence was filed on 14 Jun 2024.
- Current net transaction value: -$203,222.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRGX
transaction
Common Stock
Options Exercise
- Transaction value
- $36,045
- Shares
- +7,166
- Change %
- +6.9%
- Price
- $5.03
- Shares after
- 111,071
- Date
- 18 Sep 2024
- Ownership
- Direct
CRGX
transaction
Common Stock
Sale
- Transaction value
- $179,775
- Shares
- -7,166
- Change %
- -6.5%
- Price
- $25.09
- Shares after
- 103,905
- Date
- 18 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
CRGX
transaction
Common Stock
Options Exercise
- Transaction value
- $14,964
- Shares
- +2,975
- Change %
- +2.9%
- Price
- $5.03
- Shares after
- 106,880
- Date
- 19 Sep 2024
- Ownership
- Direct
CRGX
transaction
Common Stock
Sale
- Transaction value
- $74,457
- Shares
- -2,975
- Change %
- -2.8%
- Price
- $25.03
- Shares after
- 103,905
- Date
- 19 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRGX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,166
- Change %
- -1.3%
- Price
- $0.000000
- Shares after
- 552,490
- Date
- 18 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,166
- Exercise price
- $5.03
- Footnotes
- F4
CRGX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,975
- Change %
- -0.54%
- Price
- $0.000000
- Shares after
- 549,515
- Date
- 19 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,975
- Exercise price
- $5.03
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 25, 2024.
Footnote F2
This transaction was executed in multiple trades in prices ranging from $25.00 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F3
This transaction was executed in multiple trades in prices ranging from $25.00 to $25.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F4
25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.